tradingkey.logo

MoonLake Immunotherapeutics

MLTX

53.780USD

-0.380-0.70%
收盘 09/19, 16:00美东报价延迟15分钟
3.41B总市值
亏损市盈率 TTM

MoonLake Immunotherapeutics

53.780

-0.380-0.70%
关于 MoonLake Immunotherapeutics 公司
MoonLake Immunotherapeutics 前身为 Helix Acquisition Corp,是一家从事医疗保健行业的瑞士公司。该公司是一家临床阶段的生物制药公司,专注于开发治疗免疫疾病的药物,包括炎症性皮肤病和关节病。该公司开发了三特异性纳米抗体 Sonelokimab (SLK),其目的是靶向和穿透难以到达的发炎组织。SLK 是一种在深层皮肤和关节中富集度增强且靶标结合力强的分子。SLK 通过独立抑制引起患者炎症的天然 IL-17 A/A、A/F 和 F/F 二聚体来抑制 IL-17A 和 IL-17F 抑制以治疗炎症性疾病。
公司简介
公司代码MLTX
公司名称MoonLake Immunotherapeutics
上市日期Oct 20, 2020
CEODr. Jorge Santos Da Silva
员工数量100
证券类型Ordinary Share
年结日Oct 20
公司地址Dorfstrasse 29
城市ZUG
上市交易所NASDAQ Capital Market Consolidated
国家Switzerland
邮编6300
电话41415108022
网址https://moonlaketx.com/
公司代码MLTX
上市日期Oct 20, 2020
CEODr. Jorge Santos Da Silva
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.13M
+1.59%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
3.08M
--
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
616.67K
--
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.13M
+1.59%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
3.08M
--
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
616.67K
--
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月15日 周五
更新时间: 8月15日 周五
持股股东
股东类型
持股股东
持股股东
占比
BVF Partners L.P.
31.10%
Cormorant Asset Management, LP
13.38%
Fidelity Management & Research Company LLC
8.36%
Avoro Capital Advisors LLC
6.54%
Reich (Kristian)
4.93%
其他
35.69%
持股股东
持股股东
占比
BVF Partners L.P.
31.10%
Cormorant Asset Management, LP
13.38%
Fidelity Management & Research Company LLC
8.36%
Avoro Capital Advisors LLC
6.54%
Reich (Kristian)
4.93%
其他
35.69%
股东类型
持股股东
占比
Hedge Fund
51.75%
Investment Advisor
20.07%
Investment Advisor/Hedge Fund
19.76%
Individual Investor
11.02%
Corporation
4.39%
Research Firm
2.09%
Venture Capital
1.30%
Bank and Trust
0.07%
Pension Fund
0.07%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
326
71.15M
112.06%
-8.45M
2025Q1
329
71.47M
112.59%
-8.98M
2024Q4
308
74.57M
117.86%
+1.09M
2024Q3
292
73.42M
116.42%
+551.38K
2024Q2
282
72.21M
114.78%
+1.82M
2024Q1
274
70.82M
112.58%
-306.27K
2023Q4
260
64.82M
107.09%
-2.17M
2023Q3
219
60.33M
114.64%
-5.55M
2023Q2
175
60.28M
100.54%
+9.44M
2023Q1
123
42.29M
108.00%
-6.15M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BVF Partners L.P.
19.75M
31.12%
--
--
Mar 31, 2025
Cormorant Asset Management, LP
8.49M
13.38%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
5.43M
8.55%
-59.34K
-1.08%
Mar 31, 2025
Avoro Capital Advisors LLC
2.77M
4.36%
--
--
Mar 31, 2025
Reich (Kristian)
3.08M
4.85%
--
--
Mar 15, 2025
Santos da Silva (Jorge)
3.08M
4.85%
--
--
Mar 15, 2025
MoonLake Immunotherapeutics AG
2.79M
4.39%
+2.69M
+2715.67%
Dec 31, 2023
T. Rowe Price Associates, Inc.
2.97M
4.69%
-369.81K
-11.06%
Mar 31, 2025
Citadel Advisors LLC
1.48M
2.33%
-708.23K
-32.39%
Mar 31, 2025
Westfield Capital Management Company, L.P.
1.43M
2.26%
+123.15K
+9.39%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
ALPS Medical Breakthroughs ETF
1.92%
Global X Guru Index ETF
1.69%
Harbor Health Care ETF
1.47%
Virtus LifeSci Biotech Clinical Trials ETF
1.35%
Goldman Sachs Future Health Care Equity ETF
0.87%
iShares Health Innovation Active ETF
0.14%
Nuveen ESG Small-Cap ETF
0.11%
T Rowe Price Small-Mid Cap ETF
0.1%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.09%
Strive Small-Cap ETF
0.08%
查看更多
ALPS Medical Breakthroughs ETF
占比1.92%
Global X Guru Index ETF
占比1.69%
Harbor Health Care ETF
占比1.47%
Virtus LifeSci Biotech Clinical Trials ETF
占比1.35%
Goldman Sachs Future Health Care Equity ETF
占比0.87%
iShares Health Innovation Active ETF
占比0.14%
Nuveen ESG Small-Cap ETF
占比0.11%
T Rowe Price Small-Mid Cap ETF
占比0.1%
JPMorgan BetaBuilders US Small Cap Equity ETF
占比0.09%
Strive Small-Cap ETF
占比0.08%
分红派息
近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
KeyAI